医薬品ドラッグデリバリー市場 - 2026年までの世界予測\nホーム » 医療・医薬 » 医薬品ドラッグデリバリー市場\n医薬品ドラッグデリバリー市場: 投与経路（経口、注射器、埋め込み型、シロップ、ゲル、肺、溶液、錠剤、注射器）、適用（癌、糖尿病）、使用施設（病院）、COVID-19の影響 – 2026年までの世界予測\nPharmaceutical Drug Delivery Market by Route of Administration (Oral, Injectors, Implantable, Syrups, Gels, Pulmonary, Solutions, Tablets, Syringes), Application (Cancer, Diabetes), Facility of Use (Hospitals), COVID-19 Impact – Global Forecast to 2026\nThe global pharmaceutical drug delivery market is projected to reach USD 2,206.5 billion by 2026 from USD 1,656.9 billion in 2021, at a CAGR of 5.9% during the forecast period. Growth in the pharmaceutical drug delivery market can largely be attributed to factors such as the rising prevalence of chronic diseases, growing biologics market, increasing R&D investments, and technological advancements & new product launches.\n• By Region – North America–45%, Europe–30%, Asia–20%, Latin America- 3%, Middle East and Africa–2%\nKey players in the Pharmaceutical Drug Delivery Market\nThe report analyzes the pharmaceutical drug delivery market and aims at estimating the market size and future growth potential of this market based on various segments such as route of administration, application, facility of use, and region. The report also includes a product portfolio matrix of various pharmaceutical drug delivery available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product & service offerings, and key market strategies.\n• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global pharmaceutical drug delivery market. The report analyzes this market by route of administration, application, and facility of use\n• Solution Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global pharmaceutical drug delivery market\n• Market Development: Comprehensive information on the lucrative emerging markets by route of administration, applications, and facility of use\n• Market Diversification: Exhaustive information about new product enhancements, growing geographies, recent developments, and investments in the global pharmaceutical drug delivery market\n• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global pharmaceutical drug delivery market.\n1.2 MARKET DEFINITION AND SCOPE 45\n1.2.2 MARKETS COVERED 46\nFIGURE 1 PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION 46\n1.2.3 YEARS CONSIDERED FOR THE STUDY 46\nTABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 47\n1.4 STAKEHOLDERS 47\n1.5 SUMMARY OF CHANGES 48\nFIGURE 2 RESEARCH DESIGN 49\n2.1.1 SECONDARY RESEARCH 50\nFIGURE 3 PRIMARY SOURCES 52\n2.1.2.2 Insights from primary experts 54\n2.1.2.3 Breakdown of primaries 54\nFIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND PARTICIPANTS 54\nFIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 55\nFIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 56\nFIGURE 7 PHARMACEUTICAL DRUG DELIVERY MARKET – REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON 56\nFIGURE 8 PHARMACEUTICAL SALES APPROACH 57\nFIGURE 9 TOP-DOWN APPROACH 57\nFIGURE 10 CAGR PROJECTIONS 58\nFIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE PHARMACEUTICAL DRUG DELIVERY MARKET (2021–2026): IMPACT ON MARKET GROWTH & CAGR 59\n2.3 DATA TRIANGULATION APPROACH 61\nFIGURE 12 DATA TRIANGULATION METHODOLOGY 61\n2.6 LIMITATIONS 62\n2.6.1 METHODOLOGY-RELATED LIMITATIONS 62\n2.7 RISK ASSESSMENT 63\nTABLE 2 RISK ASSESSMENT: PHARMACEUTICAL DRUG DELIVERY MARKET 63\nFIGURE 13 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD BILLION) 64\nFIGURE 14 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION) 65\nFIGURE 15 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2021 VS. 2026 (USD BILLION) 66\nFIGURE 16 GEOGRAPHIC ANALYSIS: PHARMACEUTICAL DRUG DELIVERY MARKET 67\n4.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW 69\nFIGURE 17 GROWING PREVALENCE OF CHRONIC DISEASES AND INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH 69\n4.2 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE AND COUNTRY 70\nFIGURE 18 THE HOSPITALS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET IN 2020 70\n4.3 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71\nFIGURE 19 CHINA TO REGISTER HIGHEST REVENUE GROWTH DURING FORECAST PERIOD 71\n4.4 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION (2019-2026) 72\nFIGURE 20 NORTH AMERICA TO DOMINATE THE PHARMACEUTICAL DRUG DELIVERY MARKET DURING FORECAST PERIOD 72\n4.5 PHARMACEUTICAL DRUG DELIVERY MARKET: DEVELOPED VS. DEVELOPING MARKETS 73\nFIGURE 21 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD 73\nTABLE 3 PHARMACEUTICAL DRUG DELIVERY MARKET: IMPACT ANALYSIS 74\n5.2.1 MARKET DRIVERS 75\n5.2.1.1 Rising prevalence of chronic diseases 75\n5.2.1.2 Growth in the biologics market 76\nTABLE 4 INDICATIVE LIST OF BIOLOGICS APPROVED BY THE FDA (2020) 76\n5.2.1.3 Technological advancements and new product launches 77\n5.2.1.4 Increasing investments in pharmaceutical R&D 79\nFIGURE 22 NUMBER OF PHARMACEUTICAL COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2020) 79\nFIGURE 23 GLOBAL PHARMA R&D SPENDING (2016–2020) 79\n5.2.2 MARKET RESTRAINTS 80\n5.2.2.1 Risk of needlestick injuries 80\n5.2.3 MARKET OPPORTUNITIES 81\n5.2.3.1 Self-administration and home care 81\n5.2.3.2 Rising demand for biosimilars and biologics 81\n5.2.4 MARKET CHALLENGES 82\n5.2.4.1 Pricing pressure 82\n5.3 COVID-19 IMPACT ON THE PHARMACEUTICAL DRUG DELIVERY MARKET 82\n5.4 INDUSTRY TRENDS 84\n5.4.1 INCREASING ADOPTION OF WEARABLE DRUG DELIVERY TECHNOLOGIES 84\n5.4.2 ADVANCEMENTS IN TECHNOLOGIES AND DESIGNS 84\n5.5 REGULATORY ANALYSIS 85\nTABLE 5 REGULATORY SCENARIO BY COUNTRY 85\n5.6 PORTER’S FIVE FORCES ANALYSIS 88\nTABLE 6 PORTER’S FIVE FORCES ANALYSIS (2020): PHARMACEUTICAL DRUG DELIVERY MARKET 88\n5.6.1 THREAT FROM NEW ENTRANTS 88\n5.6.2 THREAT FROM SUBSTITUTES 88\n5.6.3 BARGAINING POWER OF SUPPLIERS 89\n5.6.4 BARGAINING POWER OF BUYERS 89\n5.6.5 INTENSITY OF COMPETITIVE RIVALRY 89\n5.7 VALUE CHAIN ANALYSIS 90\nFIGURE 24 VALUE CHAIN ANALYSIS OF THE PHARMACEUTICAL DRUG DELIVERY MARKET 90\n5.8 ECOSYSTEM MAPPING 91\nFIGURE 25 ECOSYSTEM OF THE PHARMACEUTICAL DRUG DELIVERY MARKET 91\n5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 91\n5.10.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 92\nFIGURE 26 PATENT PUBLICATION, FILING, AND GRANT TRENDS (JANUARY 2011–OCTOBER 2021) 92\n5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 92\nFIGURE 27 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2011–OCTOBER 2021) 93\nFIGURE 28 TOP APPLICANT COUNTRIES/REGIONS FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2011–OCTOBER 2021) 94\nTABLE 7 SOME PATENTS/ PATENT APPLICATIONS IN THE PHARMACEUTICAL DRUG DELIVERY MARKET, 2020-2021 94\n6 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION 96\nTABLE 8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 97\n6.2 ORAL DRUG DELIVERY 98\nTABLE 9 ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 98\nTABLE 10 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 99\n6.2.1 SOLID ORAL DRUGS 99\nTABLE 11 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 100\nTABLE 12 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY COUNTRY, 2019–2026 (USD BILLION) 100\n6.2.1.1 Tablets 101\n6.2.1.1.1 The development of mini-tablets is a key trend in this market segment 101\nTABLE 13 TABLETS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 102\n6.2.1.2 Capsules 102\n6.2.1.2.1 The easy absorption of drugs and decreased irritation in the GI tract drive the use of capsules 102\nTABLE 14 CAPSULES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 103\n6.2.1.3 Powders 103\n6.2.1.3.1 Powders are taken by patients who are unable to swallow oral dosage forms 103\nTABLE 15 POWDERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 104\n6.2.1.4 Pills 105\n6.2.1.4.1 The rising incidence of target ailments to propel the growth of the pills market 105\nTABLE 16 PILLS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 105\n6.2.2 LIQUID ORAL DRUGS 106\nTABLE 17 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 106\nTABLE 18 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 107\n6.2.2.1 Syrups 107\n6.2.2.1.1 Syrups can be easily administered to patients with swallowing difficulties 107\nTABLE 19 ORAL SYRUPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 108\n6.2.2.2 Solutions 108\n6.2.2.2.1 Solutions are generally preferred by geriatric and pediatric patients 108\nTABLE 20 ORAL SOLUTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 109\n6.2.3 SEMI SOLID ORAL DRUGS 109\nTABLE 21 ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 110\nTABLE 22 ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY COUNTRY, 2019–2026 (USD BILLION) 110\n6.2.3.1 Gels 111\n6.2.3.1.1 Gels are used for controlled drug release 111\nTABLE 23 ORAL GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 111\n6.2.3.2 Emulsions 112\n6.2.3.2.1 Microemulsions offer protection against oxidation and enzymatic hydrolysis 112\nTABLE 24 ORAL EMULSIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 112\n6.2.3.3 Elixirs 113\n6.2.3.3.1 Elixirs are hydraulic in nature and contain sweet and flavored substances 113\nTABLE 25 ORAL ELIXIRS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 113\n6.3 INJECTABLE DRUG DELIVERY 114\nTABLE 26 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 115\nTABLE 27 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 115\n6.3.1 CONVENTIONAL INJECTION DEVICES 116\nTABLE 28 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY COUNTRY, 2019–2026 (USD BILLION) 116\n6.3.1.1 By material 117\nTABLE 29 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 117\n6.3.1.1.1 Glass Syringes 117\n6.3.1.1.1.1 Glass syringes are considered to be one of the most durable and safest materials to store biological drugs 117\nTABLE 30 GLASS SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 118\n6.3.1.1.2 Plastic Syringes 118\n6.3.1.1.2.1 Plastic syringes are reasonably priced as compared to their glass counterparts 118\nTABLE 31 PLASTIC SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 119\n6.3.1.2 By product 119\nTABLE 32 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 120\n6.3.1.2.1 Fillable syringes 120\n6.3.1.2.1.1 Ease of use and the variable dosing formulations of fillable syringes to drive the market growth 120\nTABLE 33 FILLABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 121\n6.3.1.2.2 Prefilled syringes 121\n6.3.1.2.2.1 Prefilled syringes offer improved dose accuracy and increased patient convenience and safety 121\nTABLE 34 PREFILLED SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 122\n6.3.1.3 By usability 123\nTABLE 35 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 123\n6.3.1.3.1 Reusable syringes 123\n6.3.1.3.1.1 Reusable syringes are easy to dismantle and clean 123\nTABLE 36 REUSABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 124\n6.3.1.3.2 Disposable syringes 124\n6.3.1.3.2.1 Disposable syringes are widely used in medical practices due to their low cost and convenience 124\nTABLE 37 DISPOSABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 125\n6.3.2 SELF-INJECTION DEVICES 125\nTABLE 38 INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 126\nTABLE 39 INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY COUNTRY, 2019–2026 (USD BILLION) 127\n6.3.2.1 Needle-free injectors 127\n6.3.2.1.1 Needle-free injectors enable faster drug delivery and show better reproducibility as compared to invasive drug delivery systems 127\nTABLE 40 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 128\n6.3.2.2 Autoinjectors 128\n6.3.2.2.1 Autoinjectors to provide improved patient satisfaction as compared to manual injections 128\nTABLE 41 AUTOINJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 129\n6.3.2.3 Pen injectors 129\n6.3.2.3.1 Pen injectors are generally used when medications have to be administered more than once a week 129\nTABLE 42 COMMERCIALLY AVAILABLE KEY PEN INJECTORS 130\nTABLE 43 PEN INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 130\n6.3.2.4 Wearable injectors 131\n6.3.2.4.1 Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare to support market growth 131\nTABLE 44 WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 131\n6.3.3 OTHER INJECTOR DEVICES 132\nTABLE 45 OTHER INJECTORS DEVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 132\n6.4 TOPICAL DRUG DELIVERY 133\nTABLE 46 TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 133\nTABLE 47 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 134\n6.4.1 LIQUID FORMULATIONS 134\nTABLE 48 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 134\nTABLE 49 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 135\n6.4.1.1 Solutions 135\n6.4.1.1.1 Ease of use and ready availability of the dosage form to support market growth 135\nTABLE 50 TOPICAL SOLUTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 136\n6.4.1.2 Suspensions 136\n6.4.1.2.1 Factors such as the high rate of bioavailability and the controlled onset of action to support the growth of the topical suspensions market 136\nTABLE 51 TOPICAL SUSPENSIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 137\n6.4.2 SEMI SOLID FORMULATIONS 137\nTABLE 52 TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 138\nTABLE 53 TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 138\n6.4.2.1 Creams 139\n6.4.2.1.1 Creams are either water-in-oil or oil-in-water emulsions 139\nTABLE 54 TOPICAL CREAMS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 139\n6.4.2.2 Gels 140\n6.4.2.2.1 Faster drug release and greater patient acceptability to drive the market for topical gels 140\nTABLE 55 TOPICAL GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 140\n6.4.2.3 Ointments 141\n6.4.2.3.1 Ointments are widely used in analgesic indications 141\nTABLE 56 TOPICAL OINTMENTS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 141\n6.4.2.4 Pastes 142\n6.4.2.4.1 Topical pastes are widely used for the treatment and prevention of skin irritation 142\nTABLE 57 TOPICAL PASTES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 142\n6.4.2.5 Lotions 143\n6.4.2.5.1 Easy administration of lotions to drive the demand among end users 143\nTABLE 58 TOPICAL LOTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 143\n6.4.3 SOLID FORMULATIONS 144\nTABLE 59 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 144\nTABLE 60 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 144\n6.4.3.1 Suppositories 145\n6.4.3.1.1 Suppositories require a suitable base to ensure the compatibility and stability of the drug 145\nTABLE 61 TOPICAL SUPPOSITORIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 145\n6.4.3.2 Powders 146\n6.4.3.2.1 Powders have a very fine particle size that covers a large surface area per unit weight 146\nTABLE 62 TOPICAL POWDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 146\n6.4.4 TRANSDERMAL PRODUCTS 147\nTABLE 63 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 147\nTABLE 64 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2019–2026 (USD BILLION) 148\n6.4.4.1 Transdermal patches 148\n6.4.4.1.1 Transdermal patches to prevent the premature metabolization of the drug through the liver 148\nTABLE 65 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 149\n6.4.4.2 Transdermal gels 150\n6.4.4.2.1 Transdermal gels to help in a faster release of drugs on the target site 150\nTABLE 66 TRANSDERMAL GELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 150\n6.5 OCULAR DRUG DELIVERY 151\nTABLE 67 OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 151\nTABLE 68 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 152\n6.5.1 LIQUID FORMULATIONS 152\nTABLE 69 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 153\nTABLE 70 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 153\n6.5.1.1 Eye drops 154\n6.5.1.1.1 Rising prevalence of cataracts and other eye diseases to drive the market growth 154\nTABLE 71 COMMERCIALLY AVAILABLE EYE DROPS 154\nTABLE 72 EYE DROPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 155\n6.5.1.2 Liquid sprays 155\n6.5.1.2.1 Liquid sprays to help in overcoming drawbacks associated with traditional eye drops 155\nTABLE 73 LIQUID SPRAYS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 156\n6.5.2 SEMI SOLID FORMULATIONS 156\nTABLE 74 OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 157\nTABLE 75 OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 157\n6.5.2.1 Gels 158\n6.5.2.1.1 The high viscosity of drugs, prolonged drug release, and the ease of drug administration are factors contributing to market growth 158\nTABLE 76 OCULAR GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 158\n6.5.2.2 Eye ointments 159\n6.5.2.2.1 Eye ointments are safe to use and help in improving ocular contact time with the drug 159\nTABLE 77 EYE OINTMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 160\n6.5.3 OCULAR DEVICES 160\nTABLE 78 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 161\nTABLE 79 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY COUNTRY, 2019–2026 (USD BILLION) 161\n6.5.3.1 Drug-coated contact lenses 162\n6.5.3.1.1 Better eyesight offered by lenses and high compliance to drive the market for drug-coated contact lenses 162\nTABLE 80 DRUG-COATED CONTACT LENSES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 162\n6.5.3.2 Ocular inserts 163\n6.5.3.2.1 Ocular inserts to help in the sustained release of drugs in the eye 163\nTABLE 81 OCULAR INSERTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 163\n6.6 PULMONARY DRUG DELIVERY 164\nTABLE 82 PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 164\nTABLE 83 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 165\n6.6.1 METERED-DOSE INHALERS 165\n6.6.1.1 Metered-dose inhalers overcome the problem of poor coordination between inhaler actuation and patient breath 165\nTABLE 84 PULMONARY DRUG DELIVERY MARKET FOR METERED-DOSE INHALERS, BY COUNTRY, 2019–2026 (USD BILLION) 166\n6.6.2 DRY POWDER INHALERS 166\n6.6.2.1 Dry powder inhaler formulations are chemically more stable than their counterparts 166\nTABLE 85 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS, BY COUNTRY, 2019–2026 (USD BILLION) 167\n6.6.3 NEBULIZERS 167\nTABLE 86 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 168\nTABLE 87 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY COUNTRY, 2019–2026 (USD BILLION) 168\n6.6.3.1 Jet nebulizers 169\n6.6.3.1.1 Jet nebulizers account for the largest share of the nebulizers market 169\nTABLE 88 JET NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 169\n6.6.3.2 Ultrasonic nebulizers 170\n6.6.3.2.1 Ultrasonic nebulizers are easy to use and comfortable to handle 170\nTABLE 89 ULTRASONIC NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 170\n6.6.3.3 Soft mist nebulizers 171\n6.6.3.3.1 Soft mist nebulizers are preferred for the treatment of severe COPD 171\nTABLE 90 SOFT MIST NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 171\n6.7 NASAL DRUG DELIVERY 172\nTABLE 91 NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 172\nTABLE 92 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 173\n6.7.1 NASAL DROPS 173\n6.7.1.1 Nasal drops are considered more efficient than nasal sprays 173\nTABLE 93 NASAL DROPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 174\n6.7.2 NASAL SPRAYS 174\n6.7.2.1 Nasal sprays to help in relieving nasal congestion, runny nose, itchy nose, and sneezing 174\nTABLE 94 NASAL SPRAYS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 175\n6.7.3 NASAL POWDERS 175\n6.7.3.1 The absence of preservatives and superior stability of formulations are some of the advantages associated with nasal powders 175\nTABLE 95 NASAL POWDERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 176\n6.7.4 NASAL GELS 176\n6.7.4.1 Nasal gels provide long-lasting relief from dry nasal passages and also reduce irritation caused by using soothing excipients 176\nTABLE 96 NASAL GELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 177\n6.8 TRANSMUCOSAL DRUG DELIVERY 177\nTABLE 97 TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 178\nTABLE 98 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 179\n6.8.1 ORAL FORMULATIONS 179\nTABLE 99 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 180\nTABLE 100 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 180\n6.8.1.1 Buccal drug delivery 181\n6.8.1.1.1 Buccal drug delivery system is suitable for local and systematic therapies 181\nTABLE 101 BUCCAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 181\n6.8.1.2 Sublingual drug delivery 182\n6.8.1.2.1 The rate of drug absorption through the sublingual route is 3–10 times higher than the oral route 182\nTABLE 102 SUBLINGUAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 183\n6.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES 183\nTABLE 103 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 184\nTABLE 104 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 184\n6.8.2.1 Rectal transmucosal drug delivery 185\n6.8.2.1.1 The rectal route of drug delivery rapidly absorbs drugs that are aqueous in nature 185\nTABLE 105 RECTAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 185\n6.8.2.2 Vaginal transmucosal drug delivery 186\n6.8.2.2.1 The permeability of the drug is high through the vaginal route of administration 186\nTABLE 106 VAGINAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 186\n6.9 IMPLANTABLE DRUG DELIVERY 187\nTABLE 107 IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 187\nTABLE 108 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 188\n6.9.1 ACTIVE IMPLANTABLE DRUG DELIVERY 188\n6.9.1.1 Active implantable devices are used for diagnostic monitoring, body fluids transportation, and ionizing radiation 188\nTABLE 109 ACTIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 189\n6.9.2 PASSIVE IMPLANTABLE DRUG DELIVERY 189\n6.9.2.1 Passive implants primarily include joint replacements, heart valves, aneurysm clips, coronary stents, and breast implants 189\nTABLE 110 PASSIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 190\n7 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION 191\n7.2 COVID-19 IMPACT, BY APPLICATION 192\nTABLE 111 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 193\n7.3 INFECTIOUS DISEASES 193\n7.3.1 HIGH BURDEN OF INFECTIOUS DISEASES ACROSS THE GLOBE TO DRIVE MARKET GROWTH 193\nTABLE 112 PHARMACEUTICAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 195\n7.4 CANCER 195\n7.4.1 CANCER TO FORM A KEY THERAPEUTIC APPLICATION SEGMENT FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 195\nFIGURE 29 INCIDENCE OF ALL TYPES OF CANCER CASES WORLDWIDE (2020) 196\nFIGURE 30 NUMBER OF ONCOLOGY CLINICAL TRIALS GLOBALLY FROM 2010 TO 2018 (IN THOUSANDS) 196\nTABLE 113 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020) 197\nTABLE 114 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD BILLION) 198\n7.5 CARDIOVASCULAR DISEASES 198\n7.5.1 INCREASING PREVALENCE OF CVDS AND INCREASING INNOVATION IN THE PHARMACEUTICAL DRUG DELIVERY SEGMENT TO PROPEL MARKET GROWTH 198\nTABLE 115 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020) 199\nTABLE 116 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 200\n7.6 DIABETES 200\n7.6.1 EMERGENCE OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH 200\nFIGURE 31 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM 2000 TO 2045 (IN MILLIONS) 201\nTABLE 117 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY, 2019–2026 (USD BILLION) 202\n7.7 RESPIRATORY DISEASES 202\n7.7.1 HIGH PREVALENCE OF ASTHMA AND COPD TO DRIVE THE ADOPTION OF PHARMACEUTICAL DRUG DELIVERY 202\nTABLE 118 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2020) 203\nTABLE 119 PHARMACEUTICAL DRUG DELIVERY MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 204\n7.8 CENTRAL NERVOUS SYSTEM DISORDERS 204\n7.8.1 ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS ARE WIDELY USED IN THE TREATMENT OF CNS DISORDERS 204\nTABLE 120 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION) 206\n7.9 AUTOIMMUNE DISEASES 206\n7.9.1 AUTOIMMUNE DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD 206\nTABLE 121 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 207\n7.10 OTHER APPLICATIONS 208\n7.10.1 OPHTHALMIC DISORDERS 208\n7.10.2 ENDOCRINE DISORDERS 208\nTABLE 122 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 209\n8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE 210\nTABLE 123 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 211\n8.2 HOSPITALS 212\n8.2.1 HOSPITALS DOMINATE THE GLOBAL MARKET WITH THE HIGH VOLUME OF PRESCRIPTIONS FOR INPATIENT AND OUTPATIENT VISITS 212\nTABLE 124 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD BILLION) 213\n8.3 AMBULATORY SURGERY CENTERS/CLINICS 214\n8.3.1 INCREASING PREFERENCE FOR AMBULATORY SURGERY CENTERS TO RESULT IN A SIGNIFICANT RISE IN DEMAND FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 214\nTABLE 125 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2019–2026 (USD BILLION) 215\n8.4 HOME CARE SETTINGS 215\n8.4.1 HOME CARE SETTINGS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 215\nTABLE 126 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2019–2026 (USD BILLION) 216\n8.5 DIAGNOSTIC CENTERS 216\n8.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH 216\nTABLE 127 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2019–2026 (USD BILLION) 217\n8.6 OTHER FACILITIES OF USE 217\nTABLE 128 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES OF USE, BY COUNTRY, 2019–2026 (USD BILLION) 218\n9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION 219\nFIGURE 32 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT (2020) 220\nTABLE 129 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2019–2026 (USD BILLION) 221\n9.2 NORTH AMERICA 221\nFIGURE 33 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT 223\nTABLE 130 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 224\nTABLE 131 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 224\nTABLE 132 NORTH AMERICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 225\nTABLE 133 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 225\nTABLE 134 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 225\nTABLE 135 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD MILLION) 226\nTABLE 136 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 226\nTABLE 137 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 226\nTABLE 138 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 227\nTABLE 139 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 227\nTABLE 140 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 227\nTABLE 141 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 228\nTABLE 142 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 228\nTABLE 143 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 228\nTABLE 144 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 229\nTABLE 145 NORTH AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 229\nTABLE 146 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 229\nTABLE 147 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 230\nTABLE 148 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 230\nTABLE 149 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 230\nTABLE 150 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 231\nTABLE 151 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 231\nTABLE 152 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 231\nTABLE 153 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 232\nTABLE 154 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 232\nTABLE 155 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 232\nTABLE 156 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 233\nTABLE 157 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 233\nTABLE 158 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 234\n9.2.1 US 234\n9.2.1.1 The US to dominate the North American pharmaceutical drug delivery market 234\nTABLE 159 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 235\nTABLE 160 US: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 235\nTABLE 161 US: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 236\nTABLE 162 US: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 236\nTABLE 163 US: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD MILLION) 236\nTABLE 165 US: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 237\nTABLE 166 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES,\nBY MATERIAL, 2019–2026 (USD BILLION) 237\nTABLE 167 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 237\nTABLE 168 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 238\nTABLE 169 US: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 238\nTABLE 170 US: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 238\nTABLE 171 US: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 239\nTABLE 172 US: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 239\nTABLE 173 US: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 239\nTABLE 174 US: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 240\nTABLE 175 US: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 240\nTABLE 176 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 240\nTABLE 177 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 241\nTABLE 178 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 241\nTABLE 179 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 241\nTABLE 180 US: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 242\nTABLE 181 US: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 242\nTABLE 182 US: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 242\nTABLE 183 US: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 243\nTABLE 184 US: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 243\nTABLE 185 US: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 243\nTABLE 186 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 244\nTABLE 187 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 244\n9.2.2 CANADA 245\n9.2.2.1 Government support for research and the prevalence of chronic diseases to drive the market in Canada 245\nTABLE 188 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 246\nTABLE 189 CANADA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 246\nTABLE 190 CANADA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 247\nTABLE 191 CANADA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 247\nTABLE 192 CANADA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 247\nTABLE 193 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 248\nTABLE 194 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 248\nTABLE 195 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 248\nTABLE 196 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 249\nTABLE 197 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 249\nTABLE 198 CANADA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 249\nTABLE 199 CANADA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 250\nTABLE 200 CANADA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 250\nTABLE 201 CANADA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 250\nTABLE 202 CANADA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 251\nTABLE 203 CANADA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 251\nTABLE 204 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 251\nTABLE 205 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 252\nTABLE 206 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 252\nTABLE 207 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 252\nTABLE 208 CANADA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 253\nTABLE 209 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 253\nTABLE 210 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 253\nTABLE 211 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 254\nTABLE 212 CANADA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 254\nTABLE 213 CANADA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 254\nTABLE 214 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 255\nTABLE 215 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 255\n9.3 EUROPE 256\nTABLE 216 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 256\nTABLE 217 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 257\nTABLE 218 EUROPE: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 257\nTABLE 219 EUROPE: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 258\nTABLE 220 EUROPE: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 258\nTABLE 221 EUROPE: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 258\nTABLE 222 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 259\nTABLE 223 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 259\nTABLE 224 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 259\nTABLE 225 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 260\nTABLE 226 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 260\nTABLE 227 EUROPE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 260\nTABLE 228 EUROPE: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 261\nTABLE 229 EUROPE: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 261\nTABLE 230 EUROPE: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 261\nTABLE 231 EUROPE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 262\nTABLE 232 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 262\nTABLE 233 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 262\nTABLE 234 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 263\nTABLE 235 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 263\nTABLE 236 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 263\nTABLE 237 EUROPE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 264\nTABLE 238 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 264\nTABLE 239 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 264\nTABLE 240 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 265\nTABLE 241 EUROPE: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 265\nTABLE 242 EUROPE: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 265\nTABLE 243 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 266\nTABLE 244 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 266\n9.3.1 GERMANY 267\n9.3.1.1 Growing focus of pharmaceutical companies on the development of various drug delivery products to drive the market in Germany 267\nTABLE 245 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 268\nTABLE 246 GERMANY: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 268\nTABLE 247 GERMANY: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 269\nTABLE 248 GERMANY: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 269\nTABLE 249 GERMANY: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 269\nTABLE 250 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 270\nTABLE 251 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 270\nTABLE 252 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 270\nTABLE 253 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 271\nTABLE 254 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 271\nTABLE 255 GERMANY: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 271\nTABLE 256 GERMANY: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 272\nTABLE 257 GERMANY: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 272\nTABLE 258 GERMANY: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 272\nTABLE 259 GERMANY: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 273\nTABLE 260 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 273\nTABLE 261 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 273\nTABLE 262 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 274\nTABLE 263 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 274\nTABLE 264 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 274\nTABLE 265 GERMANY: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 275\nTABLE 266 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 275\nTABLE 267 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 275\nTABLE 268 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 276\nTABLE 269 GERMANY: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 276\nTABLE 270 GERMANY: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 276\nTABLE 271 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 277\nTABLE 272 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 277\n9.3.2 FRANCE 278\n9.3.2.1 Presence of leading pharmaceutical companies along with the increasing prevalence of chronic diseases to drive market growth in France 278\nTABLE 273 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 279\nTABLE 274 FRANCE: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 279\nTABLE 275 FRANCE: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 280\nTABLE 276 FRANCE: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 280\nTABLE 277 FRANCE: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 280\nTABLE 278 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 281\nTABLE 279 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 281\nTABLE 280 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 281\nTABLE 281 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 282\nTABLE 282 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD MILLION) 282\nTABLE 283 FRANCE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 282\nTABLE 284 FRANCE: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 283\nTABLE 285 FRANCE: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 283\nTABLE 286 FRANCE: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 283\nTABLE 287 FRANCE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 284\nTABLE 288 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 284\nTABLE 289 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 284\nTABLE 290 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 285\nTABLE 291 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 285\nTABLE 292 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 285\nTABLE 293 FRANCE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 286\nTABLE 294 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 286\nTABLE 295 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 286\nTABLE 296 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 287\nTABLE 297 FRANCE: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 287\nTABLE 298 FRANCE: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 287\nTABLE 299 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 288\nTABLE 300 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 288\n9.3.3 ITALY 289\n9.3.3.1 Increasing focus on clinical research and the growing popularity of branded drugs to drive the demand for pharmaceutical drug manufacturing 289\nTABLE 301 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 290\nTABLE 302 ITALY: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 290\nTABLE 303 ITALY: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 291\nTABLE 304 ITALY: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 291\nTABLE 305 ITALY: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 291\nTABLE 306 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 292\nTABLE 307 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 292\nTABLE 308 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 292\nTABLE 309 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 293\nTABLE 310 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 293\nTABLE 311 ITALY: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 293\nTABLE 312 ITALY: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 294\nTABLE 313 ITALY: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 294\nTABLE 314 ITALY: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 294\nTABLE 315 ITALY: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 295\nTABLE 316 ITALY: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 295\nTABLE 317 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 295\nTABLE 318 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 296\nTABLE 319 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 296\nTABLE 320 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 296\nTABLE 321 ITALY: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 297\nTABLE 322 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 297\nTABLE 323 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 297\nTABLE 324 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 298\nTABLE 325 ITALY: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 298\nTABLE 326 ITALY: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 298\nTABLE 327 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 299\nTABLE 328 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 299\n9.3.4 UK 300\n9.3.4.1 Increasing incidence and prevalence of chronic and infectious diseases to drive the demand for pharmaceutical drug delivery in the UK 300\nTABLE 329 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 301\nTABLE 330 UK: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 301\nTABLE 331 UK: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 302\nTABLE 332 UK: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 302\nTABLE 333 UK: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 302\nTABLE 334 UK: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 303\nTABLE 335 UK: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 303\nTABLE 336 UK: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 303\nTABLE 337 UK: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 304\nTABLE 338 UK: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 304\nTABLE 339 UK: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 304\nTABLE 340 UK: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 305\nTABLE 341 UK: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 305\nTABLE 342 UK: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 305\nTABLE 343 UK: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 306\nTABLE 344 UK: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 306\nTABLE 345 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 306\nTABLE 346 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 307\nTABLE 347 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 307\nTABLE 348 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 307\nTABLE 349 UK: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 308\nTABLE 350 UK: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 308\nTABLE 351 UK: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 308\nTABLE 352 UK: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 309\nTABLE 353 UK: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 309\nTABLE 354 UK: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 309\nTABLE 355 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 310\nTABLE 356 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 310\n9.3.5 SPAIN 311\n9.3.5.1 Increase in biologics production to support market growth 311\nTABLE 357 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 311\nTABLE 358 SPAIN: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 312\nTABLE 359 SPAIN: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 312\nTABLE 360 SPAIN: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 312\nTABLE 361 SPAIN: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 313\nTABLE 362 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 313\nTABLE 363 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 313\nTABLE 364 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 314\nTABLE 365 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 314\nTABLE 366 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 314\nTABLE 367 SPAIN: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 315\nTABLE 368 SPAIN: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 315\nTABLE 369 SPAIN: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 315\nTABLE 370 SPAIN: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 316\nTABLE 371 SPAIN: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 316\nTABLE 372 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 316\nTABLE 373 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 317\nTABLE 374 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 317\nTABLE 375 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 317\nTABLE 376 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD MILLION) 318\nTABLE 377 SPAIN: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MLLION) 318\nTABLE 378 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 318\nTABLE 379 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 319\nTABLE 380 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 319\nTABLE 381 SPAIN: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 319\nTABLE 382 SPAIN: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 320\nTABLE 383 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 320\nTABLE 384 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 321\n9.3.6 REST OF EUROPE 321\nTABLE 385 ROE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 322\nTABLE 386 ROE: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 322\nTABLE 387 ROE: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 323\nTABLE 388 ROE: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 323\nTABLE 389 ROE: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 323\nTABLE 390 ROE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 324\nTABLE 391 ROE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 324\nTABLE 392 ROE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 324\nTABLE 393 ROE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 325\nTABLE 394 ROE: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 325\nTABLE 395 ROE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 325\nTABLE 396 ROE: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 326\nTABLE 397 ROE: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 326\nTABLE 398 ROE: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 326\nTABLE 399 ROE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 327\nTABLE 400 ROE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 327\nTABLE 401 ROE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 327\nTABLE 402 ROE: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 328\nTABLE 403 ROE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 328\nTABLE 404 ROE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 328\nTABLE 405 ROE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 329\nTABLE 406 ROE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 329\nTABLE 407 ROE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 329\nTABLE 408 ROE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 330\nTABLE 409 ROE: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 330\nTABLE 410 ROE: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 330\nTABLE 411 ROE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 331\nTABLE 412 ROE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 331\n9.4 ASIA PACIFIC 332\nFIGURE 34 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT 333\nTABLE 413 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 334\nTABLE 414 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 334\nTABLE 415 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 335\nTABLE 416 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 335\nTABLE 417 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 335\nTABLE 418 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 336\nTABLE 419 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 336\nTABLE 420 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 336\nTABLE 421 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 337\nTABLE 422 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 337\nTABLE 423 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 337\nTABLE 424 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 338\nTABLE 425 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 338\nTABLE 426 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 338\nTABLE 427 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 339\nTABLE 428 ASIA PACIFIC: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 339\nTABLE 429 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 339\nTABLE 430 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 340\nTABLE 431 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 340\nTABLE 432 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 340\nTABLE 433 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 341\nTABLE 434 ASIA PACIFIC: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 341\nTABLE 435 ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 341\nTABLE 436 ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 342\nTABLE 437 ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 342\nTABLE 438 ASIA PACIFIC: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 342\nTABLE 439 ASIA PACIFIC: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 343\nTABLE 440 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 343\nTABLE 441 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 344\n9.4.1 CHINA 344\n9.4.1.1 China had the largest diabetic population in the world in 2020 344\nTABLE 442 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 345\nTABLE 443 CHINA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 346\nTABLE 444 CHINA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 346\nTABLE 445 CHINA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 346\nTABLE 446 CHINA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 347\nTABLE 447 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 347\nTABLE 448 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 347\nTABLE 449 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 348\nTABLE 450 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 348\nTABLE 451 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 348\nTABLE 452 CHINA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 349\nTABLE 453 CHINA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 349\nTABLE 454 CHINA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 349\nTABLE 455 CHINA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 350\nTABLE 456 CHINA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 350\nTABLE 457 CHINA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 350\nTABLE 458 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 351\nTABLE 459 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 351\nTABLE 460 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 351\nTABLE 461 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 352\nTABLE 462 CHINA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 352\nTABLE 463 CHINA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 352\nTABLE 464 CHINA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 353\nTABLE 465 CHINA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 353\nTABLE 466 CHINA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 353\nTABLE 467 CHINA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 354\nTABLE 468 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 354\nTABLE 469 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 355\n9.4.2 JAPAN 355\n9.4.2.1 Favorable government initiatives and increased geriatric population to drive market growth in Japan 355\nTABLE 470 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 356\nTABLE 471 JAPAN: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 357\nTABLE 472 JAPAN: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 357\nTABLE 473 JAPAN: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 357\nTABLE 474 JAPAN: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 358\nTABLE 475 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 358\nTABLE 476 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 358\nTABLE 477 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 359\nTABLE 478 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 359\nTABLE 479 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 359\nTABLE 480 JAPAN: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 360\nTABLE 481 JAPAN: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 360\nTABLE 482 JAPAN: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 360\nTABLE 483 JAPAN: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 361\nTABLE 484 JAPAN: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 361\nTABLE 485 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 361\nTABLE 486 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 362\nTABLE 487 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 362\nTABLE 488 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 362\nTABLE 489 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 363\nTABLE 490 JAPAN: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 363\nTABLE 491 JAPAN: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 363\nTABLE 492 JAPAN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 364\nTABLE 493 JAPAN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 364\nTABLE 494 JAPAN: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 364\nTABLE 495 JAPAN: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 365\nTABLE 496 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 365\nTABLE 497 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 366\n9.4.3 INDIA 366\n9.4.3.1 Growing generic demand and rising government initiatives to drive market growth in India 366\nTABLE 498 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 367\nTABLE 499 INDIA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 367\nTABLE 500 INDIA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 368\nTABLE 501 INDIA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 368\nTABLE 502 INDIA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 368\nTABLE 503 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 369\nTABLE 504 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 369\nTABLE 505 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 369\nTABLE 506 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 370\nTABLE 507 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 370\nTABLE 508 INDIA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 370\nTABLE 509 INDIA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 371\nTABLE 510 INDIA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 371\nTABLE 511 INDIA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 371\nTABLE 512 INDIA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 372\nTABLE 513 INDIA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 372\nTABLE 514 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 372\nTABLE 515 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 373\nTABLE 516 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 373\nTABLE 517 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD MILLION) 373\nTABLE 518 INDIA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 374\nTABLE 519 INDIA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 374\nTABLE 520 INDIA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 374\nTABLE 521 INDIA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 375\nTABLE 522 INDIA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 375\nTABLE 523 INDIA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 375\nTABLE 524 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 376\nTABLE 525 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 376\n9.4.4 REST OF ASIA PACIFIC 377\nTABLE 526 ROAPAC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 378\nTABLE 527 ROAPAC: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 378\nTABLE 528 ROAPAC: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 379\nTABLE 529 ROAPAC: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 379\nTABLE 530 ROAPAC: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 379\nTABLE 531 ROAPAC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 380\nTABLE 532 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 380\nTABLE 533 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 380\nTABLE 534 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 381\nTABLE 535 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 381\nTABLE 536 ROAPAC: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 381\nTABLE 537 ROAPAC: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 382\nTABLE 538 ROAPAC: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 382\nTABLE 539 ROAPAC: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 382\nTABLE 540 ROAPAC: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 383\nTABLE 541 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 383\nTABLE 542 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 383\nTABLE 543 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 384\nTABLE 544 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 384\nTABLE 545 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 384\nTABLE 546 ROAPAC: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 385\nTABLE 547 ROAPAC: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 385\nTABLE 548 ROAPAC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 385\nTABLE 549 ROAPAC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 386\nTABLE 550 ROAPAC: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 386\nTABLE 551 ROAPAC: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 386\nTABLE 552 ROAPAC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 387\nTABLE 553 ROAPAC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 387\n9.5 LATIN AMERICA 388\n9.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM 388\nTABLE 554 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 389\nTABLE 555 LATIN AMERICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 389\nTABLE 556 LATIN AMERICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 390\nTABLE 557 LATIN AMERICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 390\nTABLE 558 LATIN AMERICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 390\nTABLE 559 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 391\nTABLE 560 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 391\nTABLE 561 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 391\nTABLE 562 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 392\nTABLE 563 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 392\nTABLE 564 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 392\nTABLE 565 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 393\nTABLE 566 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 393\nTABLE 567 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 393\nTABLE 568 LATIN AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 394\nTABLE 569 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 394\nTABLE 570 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 394\nTABLE 571 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 395\nTABLE 572 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 395\nTABLE 573 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 395\nTABLE 574 LATIN AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 396\nTABLE 575 LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 396\nTABLE 576 LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 396\nTABLE 577 LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 397\nTABLE 578 LATIN AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 397\nTABLE 579 LATIN AMERICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 397\nTABLE 580 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 398\nTABLE 581 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 398\n9.6 MIDDLE EAST & AFRICA 399\n9.6.1 GOVERNMENT SUPPORT BOOSTING LOCAL PRODUCTION TO OFFER GROWTH OPPORTUNITIES FOR PHARMACEUTICAL MANUFACTURERS 399\nTABLE 582 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 400\nTABLE 583 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 400\nTABLE 584 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 401\nTABLE 585 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 401\nTABLE 586 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD MILLION) 401\nTABLE 587 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 402\nTABLE 588 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 402\nTABLE 589 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 402\nTABLE 590 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 403\nTABLE 591 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 403\nTABLE 592 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 403\nTABLE 593 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 404\nTABLE 594 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 404\nTABLE 595 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 404\nTABLE 596 MIDDLE EAST & AFRICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD MILLION) 405\nTABLE 597 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 405\nTABLE 598 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 405\nTABLE 599 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 406\nTABLE 600 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 406\nTABLE 601 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD MILLION) 406\nTABLE 602 MIDDLE EAST & AFRICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 407\nTABLE 603 MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 407\nTABLE 604 MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 407\nTABLE 605 MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 408\nTABLE 606 MIDDLE EAST & AFRICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 408\nTABLE 607 MIDDLE EAST & AFRICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 408\nTABLE 608 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 409\nTABLE 609 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 409\n10 COMPETITIVE LANDSCAPE 410\n10.1 OVERVIEW 410\n10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 410\n10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN THE PHARMACEUTICAL DRUG DELIVERY MARKET 411\n10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 412\n10.4 MARKET SHARE ANALYSIS 413\nFIGURE 36 PHARMACEUTICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2020 413\nTABLE 610 PHARMACEUTICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION 414\n10.5 COMPETITIVE BENCHMARKING 414\nTABLE 611 FOOTPRINT OF COMPANIES IN THE PHARMACEUTICAL DRUG DELIVERY MARKET 414\nTABLE 612 COMPANY PRODUCT OFFERING FOOTPRINT (20 COMPANIES) 415\nTABLE 613 COMPANY APPLICATION FOOTPRINT (20 COMPANIES) 416\nTABLE 614 COMPANY FACILITY OF USE FOOTPRINT (20 COMPANIES) 417\nTABLE 615 COMPANY REGION FOOTPRINT (20 COMPANIES) 418\n10.6 COMPETITIVE LEADERSHIP MAPPING 419\n10.6.1 STARS 419\n10.6.2 EMERGING LEADERS 419\n10.6.3 PERVASIVE PLAYERS 419\n10.6.4 PARTICIPANTS 420\nFIGURE 37 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020 420\n10.7 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS 420\n10.7.1 PROGRESSIVE COMPANIES 421\n10.7.2 DYNAMIC COMPANIES 421\n10.7.3 STARTING BLOCKS 421\n10.7.4 RESPONSIVE COMPANIES 421\nFIGURE 38 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2020) 422\n10.8 COMPETITIVE SCENARIO 422\n10.8.1 PRODUCT LAUNCHES & APPROVALS 423\n10.8.2 DEALS 424\n10.8.3 OTHER DEVELOPMENTS 425\n11 COMPANY PROFILES 426\n11.1 KEY PLAYERS 426\n11.1.1 JOHNSON & JOHNSON 426\nTABLE 619 JOHNSON & JOHNSON: BUSINESS OVERVIEW 426\nFIGURE 39 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020) 427\n11.1.2 NOVARTIS INTERNATIONAL AG 440\nTABLE 620 NOVARTIS INTERNATIONAL AG: BUSINESS OVERVIEW 440\nFIGURE 40 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2020) 441\n11.1.3 F. HOFFMANN-LA ROCHE AG 449\nTABLE 621 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 449\nFIGURE 41 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020) 450\n11.1.4 PFIZER INC. 455\nTABLE 622 PFIZER INC. : BUSINESS OVERVIEW 455\nFIGURE 42 PFIZER INC.: COMPANY SNAPSHOT (2020) 456\n11.1.5 BECTON, DICKINSON AND COMPANY 468\nTABLE 623 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 468\nFIGURE 43 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 469\n11.1.6 GLAXOSMITHKLINE PLC 474\nTABLE 624 GLAXOSMITHKLINE PLC: BUSINESS OVERVIEW 474\nFIGURE 44 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2020) 475\n11.1.7 MERCK & CO., INC. 483\nTABLE 625 MERCK & CO., INC.: BUSINESS OVERVIEW 483\nFIGURE 45 MERCK & CO., INC.: COMPANY SNAPSHOT (2020) 484\n11.1.8 SANOFI 491\nTABLE 626 SANOFI: BUSINESS OVERVIEW 491\nFIGURE 46 SANOFI: COMPANY SNAPSHOT (2020) 492\n11.1.9 BAYER AG 498\nTABLE 627 BAYER AG: BUSINESS OVERVIEW 498\nFIGURE 47 BAYER AG: COMPANY SNAPSHOT (2020) 499\n11.1.10 3M 505\nTABLE 628 3M: BUSINESS OVERVIEW 505\nFIGURE 48 3M: COMPANY SNAPSHOT (2020) 506\n11.1.11 ANTARES PHARMA, INC. 508\nTABLE 629 ANTARES PHARMA, INC.: BUSINESS OVERVIEW 508\n11.1.12 AMGEN, INC. 510\nTABLE 630 AMGEN, INC. : BUSINESS OVERVIEW 510\nFIGURE 49 AMGEN, INC. : COMPANY SNAPSHOT (2020) 510\n11.1.13 ABBVIE INC. 514\nTABLE 631 ABBVIE INC.: BUSINESS OVERVIEW 514\n11.1.14 GENMAB A/S 517\nTABLE 632 GENMAB A/S : BUSINESS OVERVIEW 517\n11.1.15 GILEAD SCIENCES, INC. 519\nTABLE 633 GILEAD SCIENCES, INC.: BUSINESS OVERVIEW 519\n11.1.16 BOEHRINGER INGELHEIM 523\nTABLE 634 BOEHRINGER INGELHEIM: BUSINESS OVERVIEW 523\nFIGURE 50 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2020) 524\n11.1.17 ASTRAZENECA PLC 527\nTABLE 635 ASTRAZENECA PLC: BUSINESS OVERVIEW 527\nFIGURE 51 ASTRAZENECA: COMPANY SNAPSHOT (2020) 528\n11.1.18 ELI LILLY AND COMPANY 531\nTABLE 636 ELI LILLY AND COMPANY: BUSINESS OVERVIEW 531\nFIGURE 52 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2020) 532\n11.1.19 TEVA PHARMACEUTICAL INDUSTRIES LTD. 535\nTABLE 637 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW 535\n11.1.20 BRISTOL-MYERS SQUIBB 538\nTABLE 638 BRISTOL-MYERS SQUIBB: BUSINESS OVERVIEW 538\n11.2 OTHER PLAYERS 540\n11.2.1 GERRESHEIMER AG 540\n11.2.2 BOSTON SCIENTIFIC CORPORATION 541\n11.2.3 NIMBUS THERAPEUTICS 542\n11.2.4 KITE PHARMA 543\n11.2.5 IDEAYA BIOSCIENCES, INC. 544\n12 APPENDIX 545\n12.1 INSIGHTS FROM INDUSTRY EXPERTS 545\n12.2 DISCUSSION GUIDE 546\n12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 552\n12.4 AVAILABLE CUSTOMIZATIONS 554\n12.5 RELATED REPORTS 554\n12.6 AUTHOR DETAILS 555\n← 乳製品加工機器市場 宇宙状況認識市場 →


Bella's Hair Comb Twilight Breaking Dawn - White Hvidt: Merkado sa Lungsod sa Batuan nasunog\nMokabat ngadto sa napulo ka mga stalls sa Batuan Public Market ang nasunog gumikan lamang sa faulty electrical wiring niadtong nakalabay nga gabii. Nasayran sa taho nga nagsugod mga alas 11:55 sa gabii niadtong Martes didto sa usa ka Baguio Electrical Supplies nga gipanag-iyahan sa usa ka Dodong Baguio.\nSi SPO2 Eduardo Ramara sa Batuan Police Station nibutyag nga dali ra ningkatap ang kalayo sa kasikbit nga mga stalls sa atubangan sa merkado nga naglinya padulong sa direksyon sa lungsod sa Bilar. Samtang ang direksyon sa lungsod sa Carmen wala malakip.\nMatud ni Ramara nga ningkabat pa ngadto sa 20 ka minutos nga nakaabot ang firetruck gikan sa lungsod sa Carmen ug nisunod ang kabomberohan gikan sa Lungsod sa Balilihan, Loay, Trinidad, Ubay, Talibon, Valencia ug Dimiao.\nGibana banaang moabot ngadto sa P700mil ang inisyal nga danyos apan gilantaw kini nga modako pa kun matapos ang gihimo nga imbestigasyon. Dugang ni Ramara nga ilang gidudahan nga electrical short-circuit ang hinungdan sa maong sunog. (Andy Nalzaro with reports from Amado-Carmen correspondent)\nRead more @ BoholNewsDaily


Poinsett County - Wikipedia\nTiganos: 35°34′27″N 90°39′47″W / 35.57404°N 90.66293°V / 35.57404; -90.66293\nPoinsett County (Comté de Poinsett)\n35°34′27″N 90°39′47″W / 35.57404°N 90.66293°V / 35.57404; -90.66293\nHarrisburg (kapital sa kondado sa Tinipong Bansa, Arkansas)\nKondado ang Poinsett County (Prinanses: Comté de Poinsett, Kinatsila: Condado de Poinsett) sa Tinipong Bansa. Nahimutang ni sa estado sa Arkansas, sa habagatan-sidlakang bahin sa nasod, 1,300 km sa kasadpan sa Washington, D.C. Adunay 24,583 ka molupyo. Naglangkob kin og 1,977 ka kilometro kwadrado. Poinsett County mopakigbahin sa usa ka utlanan sa Craighead County, ug Cross County ang ulohan sa nasod.\nAng yuta sa Poinsett County kay patag.[saysay 1]\nMga lungsod sa Poinsett County:\nSa mosunod nga mga natural nga mga bahin makita sa Poinsett County:\nHatchie Coon Lake (kalapukan)\nAsh Spread (suba)\nBale Brown Branch (suba)\nDillard Cut off (suba)\nDistress Creek (suba)\nHydrick Creek (suba)\nIron Mines Creek (suba)\nKaylo Creek (suba)\nLead Fork (suba)\nLeft Hand Chute of Little River (suba)\nMink Slough (suba)\nMorgan Slough (suba)\nOld Channel Cache River (suba)\nOld Forked Slough (suba)\nPowers Slough (suba)\nRaccoon Bayou (suba)\nRight Hand Chute Little River (suba)\nAsh Spread Ditch (kanal)\nDitch Number 103 (kanal)\nDitch Number 105 (kanal)\nDitch Number 108 (kanal)\nDitch Number 109 (kanal)\nDitch Number 2a (kanal)\nDitch Number 41a (kanal)\nDitch Number 42a (kanal)\nDitch Number 45a (kanal)\nDitch Number 45b (kanal)\nDitch Number 47a (kanal)\nDitch Number 51a (kanal)\nDitch Number 51b (kanal)\nDitch Number 77 (kanal)\nDitch Number 78 (kanal)\nDitch Number 81 (kanal)\nDitch Number 86a (kanal)\nDitch Number 87 (kanal)\nFlag Slough Ditch (kanal)\nLanders Ditch (kanal)\nPecan Lateral (kanal)\nClaypool Reservoir (tubiganan)\nDead Timber Lake (lanaw)\nJohn Kocher Lake (tubiganan)\nLake Hogue (tubiganan)\nLake Poinsett (tubiganan)\nLonnie Jaynes Lake (tubiganan)\nLost Trap Lake (lanaw)\nO K Lake (tubiganan)\nPaul Senteny Lake (tubiganan)\nPoinsett Watershed Site 101 Reservoir (tubiganan)\nPoinsett Watershed Site 102 Reservoir (tubiganan)\nPoinsett Watershed Site One Reservoir (tubiganan)\nPoinsett Watershed Site Three Reservoir (tubiganan)\nPoinsett Watershed Site Two Reservoir (tubiganan)\nSnake Slough (lanaw)\nWayne Carter Lake (tubiganan)\nCaney Bottoms (patag)\nCow Island (patag)\nHatchie Coon Island (patag)\nMiddle Island (patag)\nOak Donnick Floodway (patag)\nOld River Island (patag)\nSaint Francis Sunk Lands (patag)\nMiller Mound (bukid)\nCummins Bar (piliw)\nAng klima umogon ug subtropikal. Ang kasarangang giiniton 15 °C. Ang kinainitan nga bulan Hunyo, sa 26 °C, ug ang kinabugnawan Disyembre, sa 4 °C. Ang kasarangang pag-ulan 1,351 milimetro matag tuig. Ang kinabasaan nga bulan Hunyo, sa 164 milimetro nga ulan, ug ang kinaugahan Nobiyembre, sa 56 milimetro.\nNahimutangan sa Poinsett County sa Tinipong Bansa.\n↑ 1.0 1.1 1.2 Poinsett County sa Geonames.org (cc-by); post updated 2013-03-07; database download sa 2017-02-28\nGikuha gikan sa "https://ceb.wikipedia.org/w/index.php?title=Poinsett_County&oldid=28062312"


Watch Super Robot Taisen OG The Inspector Episode 25 in English Subbed Online\nAnime Subbed >\tSuper Robot Taisen OG The Inspector >\tSuper Robot Taisen OG The Inspector Episode 25\nClick on "Video Mirrors" tab for different video version of Super Robot Taisen OG The Inspector 25 !!!\n*You are currently watching or downloading Super Robot Taisen OG The Inspector Episode 25 online for free in english subbed at animesub.tv. If you love Super Robot Taisen OG The Inspector, feel free to rate, leave review comments or share it with your friends.\n*Tags: Super Robot Taisen OG The Inspector 25 fansubs, streaming online, watch Super Robot Taisen OG The Inspector, Super Robot Wars OG: The Inspector, Super Robot Taisen Original Generation: The Inspector, SRWOG Episode 25 english subbed, free download Super Robot Taisen OG The Inspector Ep 25 sub, eng subbed\nNext: Super Robot Taisen OG The Inspector Episode 26\nPrevious: Super Robot Taisen OG The Inspector Episode 24


2 INCH SADDLEBAG EXTENSIONS\nHome > SADDLEBAGS & ACCESSORIES > Stretched Saddlebags > Bad Dad > 2 Inch Saddlebag Extensions\nSelect Exhaust Cut-Outs: Duals2-into-1No Cuts\nBAD DAD 2" SADDLEBAG EXTENSIONS\nGive your stock saddlebags a little extra length without going all the way to the ground. Additionally, the length of these extensions match perfectly with the length of stock Street Glide rear fenders.\nHigh quality, hand laid fiberglass. Extremely rigid fiberglass with a smooth gelcoat that is always pinhole free. Increased flanges on saddlebag extensions for perfect fit and excellent adhesive contact. Exhaust ports available for single, dual, or no exhaust pipes so you can tailor fit the port openings to your pipes. Compatible with both fiberglass and ABS style saddlebags.


Ipagawas Ang Inyung Gibati - Page 27 - Tubag Bohol With Mike Ligalig\nAuthor Topic: Ipagawas Ang Inyung Gibati (Read 565943 times)\n« Reply #1040 on: April 27, 2009, 07:21:28 pm »\nasa naman diay tong anino nimo dong\nwa na mopakita kay hayag daw.\n« Reply #1041 on: April 27, 2009, 10:12:47 pm »\nbulanon ra diay na siya mo pakita nimo\n« Reply #1042 on: April 27, 2009, 10:32:06 pm »\nwa jud na mopakita.maajo rapud oi linaw na ko\n« Reply #1043 on: April 27, 2009, 10:32:41 pm »\ngibati ko ug ka busog karon\n« Reply #1044 on: April 27, 2009, 10:34:45 pm »\nnabalaka ako karon\n« Reply #1045 on: April 27, 2009, 10:36:34 pm »\najaw laman kabalaka di lagi na mawala\n« Reply #1046 on: April 27, 2009, 10:37:42 pm »\nunsa ang di mawala vits\n« Reply #1047 on: April 27, 2009, 10:39:01 pm »\nang imong gikabalak-an\n« Reply #1048 on: April 27, 2009, 11:20:18 pm »\nhoy, pangatog na mo kay alingog-ngog. namata akong bata. hahahaha\n« Reply #1049 on: April 27, 2009, 11:22:39 pm »\nkabalo baka vits nga hapit na mawala mao nabalaka ako\n« Reply #1050 on: April 27, 2009, 11:24:06 pm »\ndokdok sa glace,ako usa mo bantay sa imo bata, andami laman ug gatas para ako paslakan ug mo lihok\n« Reply #1051 on: April 27, 2009, 11:24:17 pm »\nnagmata pa diay ka glac.sige 5 minutes tog nako\n« Reply #1052 on: April 27, 2009, 11:25:01 pm »\npasagdi ra gud ug mawala anad na bitaw ka na kanunay kawad-an\n« Reply #1053 on: April 27, 2009, 11:26:47 pm »\nkapoy mangupras dong,mao ako jud gibantayan nga di kawaton ang ako binuwad...hahahaha\n« Reply #1054 on: April 27, 2009, 11:27:57 pm »\nhahahah bantayi jud aron mauga ug dali\n« Reply #1055 on: April 27, 2009, 11:29:15 pm »\nmao jud para naa koy e plete paingon sa sugbo.\n« Reply #1056 on: April 27, 2009, 11:29:49 pm »\nplete padung langit mist\n« Reply #1057 on: April 27, 2009, 11:31:17 pm »\nway problema sa langit vits,naa daw mo libre naku,hahaha\n« Reply #1058 on: April 27, 2009, 11:34:42 pm »\ntog nako oi ugma napud mist .katog na diha aron imong madamgohan tong imong gikabalak-an\n« Reply #1059 on: April 27, 2009, 11:34:57 pm »\nnag labad akong ulo\n« Reply #1060 on: April 27, 2009, 11:37:12 pm »\ntake a deep breath & relax...then smile...\n« Reply #1061 on: April 27, 2009, 11:38:27 pm »\nim hungry today, but i really dont feel like cooking. should i marinate adobo or should i just eat eggs and onions? hmm\nbah! I miss mommy's cooking~~\n« Reply #1062 on: April 27, 2009, 11:39:15 pm »\nnah, mabuang jud ka anang smile smile nga ikaw ra usa\n« Reply #1063 on: April 27, 2009, 11:39:47 pm »\nGikapoy kog ngisi ug dokdok\n« Reply #1064 on: April 27, 2009, 11:42:03 pm »\ngalabad ug basa sa post ni vito ug misty\n« Reply #1065 on: April 27, 2009, 11:56:50 pm »\nSensya na mari. Peace.\n« Reply #1066 on: April 27, 2009, 11:58:13 pm »\nTan-aw lang sa mirror para duha imo makita,hahaha\n« Reply #1067 on: April 28, 2009, 12:08:24 am »\nhindi ako mapalagay (toinkz)\n« Reply #1068 on: April 28, 2009, 12:10:31 am »\n« Reply #1069 on: April 28, 2009, 04:08:16 am »\nkatogon or katohogon...\n« Reply #1070 on: April 28, 2009, 06:06:39 am »\nhay mingaw diko makauli sa fiesta sa amoa karong mayo 5 sa mabini kay di nisugot akong bu**** na amo....\n« Reply #1071 on: April 28, 2009, 06:19:54 am »\nIntawon pod. Pasensya na lang, basin sunod pijasta makapauli ka.\n« Reply #1072 on: April 28, 2009, 06:35:11 am »\nlubaon kuna lang to arong wa nay mopugong siya nalang akong ihanda sa fiesta pohon ..\n« Reply #1073 on: April 28, 2009, 08:27:46 am »\nSobra ka busog.\n« Reply #1074 on: April 28, 2009, 08:49:30 am »\nnaunsa ba ko. nisaka kos taas aron magkuha og POLVORON, namawong na man hinoon kos suga sa kwarto...(nakamatikod ko ani kay pagdok-dok nako diri og sugod, nangita kos polvoron, wa man hahahaha..anak). tigols na.\n« Reply #1075 on: April 28, 2009, 10:40:07 am »\nhahaha mao nay ge ngo-a ngo-a na glace kalajo ra sa polvoron ug suga ga-e noon ko polvoron be hehehe\nako gud pugos aho anak laag sa gwas kay nice warm and sunny nadagmag bitaw sus nibotoy iya lips,ug buna unja naa gas-gas sa iya ilong now i hate myself\n« Reply #1076 on: April 28, 2009, 11:10:35 am »\nkalooy sa bata. dili lang pod unta itulod. lelz.\ndiay polvoron o. ipakaon niya.\n« Reply #1077 on: April 28, 2009, 11:15:01 am »\nwala getulod oy dagmag lang,ay ako lang moka-on ana polvoron,asa man na gipalit?\n« Reply #1078 on: April 28, 2009, 11:22:46 am »\nwow kalami aning polvoron, glace! panghatag oi!\n« Reply #1079 on: April 28, 2009, 12:31:00 pm »\nnaglain akong lawas


MacGregor - Wikipedia\nTiganos: 49°57′58″N 98°46′46″W / 49.96613°N 98.77937°V / 49.96613; -98.77937\n49°57′58″N 98°46′46″W / 49.96613°N 98.77937°V / 49.96613; -98.77937\n921 gikan sa frwiki\nLungsod ang MacGregor sa Kanada. Nahimutang ni sa lalawigan sa Manitoba, sa habagatan-sidlakang bahin sa nasod, 1,800 km sa kasadpan sa Ottawa ang ulohan sa nasod. 293 metros ibabaw sa dagat kahaboga ang nahimutangan sa MacGregor, ug adunay 921 ka molupyo.\nAng yuta palibot sa MacGregor kay patag.[saysay 1] Ang kinahabogang dapit sa palibot dunay gihabogon nga 362 ka metro ug 9.9 km sa habagatan-kasadpan sa MacGregor.[saysay 2] Dunay mga 2 ka tawo kada kilometro kwadrado sa palibot sa MacGregor may kaayo gamay nga populasyon. Walay laing lungsod sa palibot niini. Hapit nalukop sa kaumahan ang palibot sa MacGregor. Sa rehiyon palibot sa MacGregor, mga kanal talagsaon komon.[saysay 3]\nAng klima hemiboreal. Ang kasarangang giiniton 3 °C. Ang kinainitan nga bulan Hulyo, sa 20 °C, ug ang kinabugnawan Enero, sa -16 °C. Ang kasarangang pag-ulan 569 milimetro matag tuig. Ang kinabasaan nga bulan Mayo, sa 101 milimetro nga ulan, ug ang kinaugahan Pebrero, sa 8 milimetro.\nNahimutangan sa MacGregor sa Kanada.\n↑ 1.0 1.1 1.2 MacGregor sa Geonames.org (cc-by); post updated 2008-04-11; database download sa 2015-12-29\nGikuha gikan sa "https://ceb.wikipedia.org/w/index.php?title=MacGregor&oldid=25989027"